COR vs HSIC — Key Metrics

Metric COR (CENCORA INC) HSIC (HENRY SCHEIN INC)
Price348.3185.69
Market Cap66.47 Billion9.47 Billion
P/E (TTM)25.7623.29
P/B (Quarterly)19.8412.887
P/S (TTM)0.20.69
Net Profit Margin (TTM)0.83.1
Gross Margin (TTM)4.031.6
ROE (TTM)106.413.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

CENCORA INC
vs
 
HENRY SCHEIN INC
 
CENCORA INC
vs
 
HENRY SCHEIN INC
Performance Comparison
AI Model Recommendation
COR · CENCORA INC

Outperform

53
UnderperformOutperform
HSIC · HENRY SCHEIN INC

Greatly Outperform

61
UnderperformOutperform
Recommendation Summary

Stock COR is projected to outperform the market, stock HSIC is projected to greatly outperform the market. Upfront Recommendation: HSIC.

Financial Metrics
Prices delayed ~15 min
COR Metrics HSIC
$348.31 Price $85.69
— Market Capitalization —
25.76 Price to Earnings Ratio 23.29
0.2 Price to Sales 0.69
16.19 Price to FCF Ratio 18.94
5.03 Price to Gross Profit 2.18
1.2 Price to Current Assets 1.98

COR vs HSIC at a glance

Cencora INC (COR) and Henry Schein INC (HSIC) are both Medical Distribution companies in the Healthcare sector. COR is the larger, at $66.5 billion in market value against $9.5 billion for HSIC, about 7.0 times the size.

On trailing-twelve-month figures, COR trades at 25.8 times trailing earnings and HSIC at 23.3; net profit margins are 0.8% and 3.1%.

The Upfront Investment model currently rates COR Outperform and HSIC Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.